Trial Profile
Phase II Study of bevacizumab plus either temozolomide or etoposide for (GBM) [glioblastoma] patients who have failed bevacizumab plus irinotecan
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 May 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Etoposide (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 May 2008 Status change from initiated to in progress, according to clinicaltrials.gov.
- 15 Mar 2008 New trial record.